Tower Research Capital LLC (TRC) - LIGAND PHARMACEUTICALS INC ownership

LIGAND PHARMACEUTICALS INC's ticker is LGND and the CUSIP is 53220K504. A total of 283 filers reported holding LIGAND PHARMACEUTICALS INC in Q3 2019. The put-call ratio across all filers is 6.41 and the average weighting 0.2%.

Quarter-by-quarter ownership
Tower Research Capital LLC (TRC) ownership history of LIGAND PHARMACEUTICALS INC
ValueSharesWeighting
Q3 2023$66,092
+182.9%
1,103
+240.4%
0.00%
+100.0%
Q2 2023$23,360
+61373.7%
324
-37.6%
0.00%0.0%
Q1 2023$38
-51.3%
519
-55.3%
0.00%
-66.7%
Q4 2022$78
-100.0%
1,161
-66.8%
0.00%
-40.0%
Q3 2022$301,000
-39.8%
3,492
-37.7%
0.01%
-54.5%
Q2 2022$500,000
+147.5%
5,601
+211.9%
0.01%
+450.0%
Q1 2022$202,000
-63.5%
1,796
-49.9%
0.00%
-80.0%
Q4 2021$554,000
+179.8%
3,587
+152.8%
0.01%
+100.0%
Q3 2021$198,000
+47.8%
1,419
+39.0%
0.01%
+66.7%
Q2 2021$134,000
-21.6%
1,021
-8.9%
0.00%0.0%
Q1 2021$171,000
+98.8%
1,121
+29.1%
0.00%0.0%
Q4 2020$86,000
-30.1%
868
-33.0%
0.00%
+200.0%
Q3 2020$123,000
-68.5%
1,295
-62.9%
0.00%
-93.8%
Q2 2020$390,000
+19400.0%
3,491
+11536.7%
0.02%
Q1 2020$2,000
-99.1%
30
-98.7%
0.00%
-100.0%
Q4 2019$232,000
+792.3%
2,227
+759.8%
0.02%
+850.0%
Q3 2019$26,0000.0%259
+13.6%
0.00%0.0%
Q2 2019$26,000
+160.0%
228
+188.6%
0.00%
+100.0%
Q1 2019$10,000
-63.0%
79
-60.3%
0.00%
-50.0%
Q4 2018$27,000
+800.0%
199
+1226.7%
0.00%
Q2 2018$3,000
-85.0%
15
-89.6%
0.00%
-100.0%
Q4 2017$20,000
-89.8%
144
-90.0%
0.00%
-81.2%
Q3 2017$197,000
+579.3%
1,445
+514.9%
0.02%
+433.3%
Q2 2017$29,000
+45.0%
235
+20.5%
0.00%
+50.0%
Q4 2016$20,000
+81.8%
195
+74.1%
0.00%
+100.0%
Q3 2016$11,000
-21.4%
112
-7.4%
0.00%0.0%
Q2 2016$14,000
-22.2%
121
-27.5%
0.00%
-66.7%
Q4 2015$18,000
-43.8%
167
-47.5%
0.00%0.0%
Q2 2015$32,000
-74.4%
318
-80.4%
0.00%
-80.0%
Q1 2015$125,000
+681.2%
1,622
+440.7%
0.02%
+650.0%
Q4 2014$16,000
+23.1%
300
+9.5%
0.00%
+100.0%
Q3 2014$13,000
-74.5%
274
-66.5%
0.00%
-85.7%
Q2 2014$51,000
+240.0%
819
+265.6%
0.01%
+250.0%
Q1 2014$15,000
+1400.0%
224
+729.6%
0.00%
Q3 2013$1,000
-98.8%
27
-98.8%
0.00%
-100.0%
Q2 2013$86,0002,3020.01%
Other shareholders
LIGAND PHARMACEUTICALS INC shareholders Q3 2019
NameSharesValueWeighting ↓
Knott David M Jr 115,000$12,937,0004.12%
Stonepine Capital Management, LLC 73,700$8,291,0003.44%
VILLERE ST DENIS J & CO LLC 510,843$57,464,0003.41%
Chicago Capital, LLC 491,717$55,313,0002.38%
Orchard Capital Management, LLC 73,596$8,279,0002.35%
RICE HALL JAMES & ASSOCIATES, LLC 344,969$38,806,0001.55%
Smith, Graham & Co., Investment Advisors, LP 86,834$9,768,0001.02%
WOODSTOCK CORP 64,050$7,205,0000.84%
INVESTMENT MANAGEMENT OF VIRGINIA LLC 37,246$4,190,0000.74%
Stephens Investment Management Group LLC 417,670$46,984,0000.69%
View complete list of LIGAND PHARMACEUTICALS INC shareholders